Here are what the editors at HealthDay consider to be the most important developments in Nephrology for June 2011. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Ambulatory BP Monitoring Can Predict Renal, Cardiac Risk
TUESDAY, June 28 (HealthDay News) -- In patients with chronic kidney disease (CKD), ambulatory blood pressure (BP) monitoring, especially at night, may predict renal and cardiovascular risks better than office BP measurements, according to a study published in the June 27 issue of the Archives of Internal Medicine.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
FDA Changes Erythropoiesis-Stimulating Agent Dosing
FRIDAY, June 24 (HealthDay News) -- The U.S. Food and Drug Administration has recommended more conservative dosing guidelines for the use of erythropoiesis-stimulating agents (ESAs) in the treatment of anemia associated with chronic kidney disease, as these drugs are tied to an increased risk of cardiovascular events.
More Information
Syndrome Caused by E. coli Mostly in Adults, Women
WEDNESDAY, June 22 (HealthDay News) -- A large, ongoing outbreak of the hemolytic-uremic syndrome caused by Shiga-toxin-producing Escherichia coli (E. coli) in Germany is occurring mostly in adults, primarily women, according to a study published online June 22 in the New England Journal of Medicine.
Abstract
Full Text (subscription or payment may be required)
Increased Prevalence of Diabetic Kidney Disease
WEDNESDAY, June 22 (HealthDay News) -- The prevalence of diabetic kidney disease (DKD) in the United States increased between 1988 and 2008 in proportion to the prevalence of diabetes, according to a study published online June 22/29 in the Journal of the American Medical Association.
Abstract
Full Text (subscription or payment may be required)
Generic Versions of Levofloxacin Approved
MONDAY, June 20 (HealthDay News) -- The first generic versions of levofloxacin, prescribed under the brand name Levaquin, have been approved by the U.S. Food and Drug Administration.
National Library of Medicine
Donor-Derived Lymphomas Mostly Develop in Allograft
FRIDAY, June 17 (HealthDay News) -- The majority of post-transplant lymphoproliferative disorders (PTLDs) that are localized in the allograft are of donor origin and are diagnosed earlier, according to a study published in the June issue of the American Journal of Transplantation.
Abstract
Full Text (subscription or payment may be required)
Nulojix Approved to Help Thwart Kidney Rejection
THURSDAY, June 16 (HealthDay News) -- Nulojix (belatacept) has been approved by the U.S. Food and Drug Administration to prevent rejection of a transplanted kidney in adults.
kidney transplant
Unequal Care Access for Children With Public Insurance
THURSDAY, June 16 (HealthDay News) -- Access to outpatient care is restricted for children with public insurance compared to those with private insurance, according to a study published in the June 16 issue of the New England Journal of Medicine.
Full Text (subscription or payment may be required)
Life Expectancy in U.S. Counties Below Many Nations
WEDNESDAY, June 15 (HealthDay News) -- Most counties within the United States fall behind the international frontier with the best life expectancies in the world, according to a study published online June 15 in Population Health Metrics.
Abstract
Full Text
FGF-23 Linked to End-Stage Renal Disease and Death
WEDNESDAY, June 15 (HealthDay News) -- In patients with chronic kidney disease, elevated fibroblast growth factor 23 (FGF-23) is associated with end-stage renal disease and death, according to a study published in the June 15 issue of the Journal of the American Medical Association.
Abstract
Full Text (subscription or payment may be required)
Similar Number for Outpatient, Inpatient Malpractice Claims
TUESDAY, June 14 (HealthDay News) -- The number of paid malpractice claims is similar in both inpatient and outpatient settings, according to a study published in the June 15 issue of the Journal of the American Medical Association.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Simvastatin Plus Ezetimibe Effective in Kidney Disease
THURSDAY, June 9 (HealthDay News) -- For patients with chronic kidney disease, lowering of low density lipoprotein (LDL) cholesterol with simvastatin and ezetimibe may reduce the risk of major atherosclerotic events, according to a study published online June 9 in The Lancet.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Youth Bear Large Burden of Global Death, Disease
TUESDAY, June 7 (HealthDay News) -- Youths between the ages of 10 and 24 years carry 15.5 percent of the global burden of disability-adjusted life-years (DALYs), according to a study published online June 7 in The Lancet.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Ban on Organs From HIV Donors Limits Availability
FRIDAY, June 3 (HealthDay News) -- Reversing the ban on the transplantation of organs from deceased donors infected with HIV (HIVDD) would have a far-reaching public health impact due to the existence of a substantial pool of potential donors who could potentially donate to HIV-positive recipients, according to a study published online March 28 in the American Journal of Transplantation.
Abstract
Full Text (subscription or payment may be required)
Bovine Serum Albumin Linked to Membranous Nephropathy
THURSDAY, June 2 (HealthDay News) -- Some patients with childhood membranous nephropathy have circulating bovine serum albumin and anti-bovine serum antibodies, which co-localize to form immune deposits, according to a study published in the June 2 issue of the New England Journal of Medicine.
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
